Key points are not available for this paper at this time.
检查点抑制剂治疗在多种肿瘤类型中显示了总体生存获益。肿瘤突变负荷（TMB）是预测免疫治疗反应的生物标志物。本研究基于利用肿瘤组织（tTMB）或血液中循环肿瘤DNA（bTMB）评估的TMB状态，评估了nivolumab+ipilimumab在多种肿瘤类型中的疗效。
Building similarity graph...
Analyzing shared references across papers
Loading...
Michael Schenker
Mauricio Burotto
Martin Eduardo Richardet
Journal for ImmunoTherapy of Cancer
McGill University
KU Leuven
National University of Singapore
Building similarity graph...
Analyzing shared references across papers
Loading...
Schenker等人（周四）研究了该问题。
www.synapsesocial.com/papers/68e5dc44b6db643587571771 — DOI: https://doi.org/10.1136/jitc-2024-008872